الفهرس 
Evaluation of the role of high mobility group box 1 protein in keloid patients
ContentsOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Background: Keloids may cause cosmetic problem to patients and may also cause pain and pruritus. Different modes of therapy that are currently being used are limited by their efficacy and side effects. HMGB1 may play a role in keloid pathogenesis so the therapeutic potential of Box A1, anti RAGE antibody and other inhibitors of HMGB1 may play a role in treatment of keloid. Objective: To evaluate role of HMGB1 in keloid patients by comparing its serum level in patients and healthy control. Methods: Forty cases of keloid and forty control were enrolled in this study. Detailed history and clinical evaluation (including determining their Fitz Patrick skin type) The Vancouver scar scale (VSS) and modified VSS. A 3 ml of whole blood was obtained from 40 keloid patients and 40 control to be centrifuged immediately then supernatant serum is kept frozen in-20 Celsius for detection and quantification of HMGB-1 protein using enzyme-linked immunosorbent assay (ELISA) technique. Results: There was a statistical significant elevation in the mean value of HMGB1 in cases (74.38±40.16) compared to the mean value of HMGB1 in control (52.00±5.41) with a p value of 0.001.and was positively correlated with the severity. Conclusion: HMGB1 was found to be elevated in keloid patients compared to their controls which suggests its role in excessive scarring and the role of its antagonists in the therapy